drugset / Trial / NCT06559436

Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke

NCT06559436

RandomizedParallel-groupSingle-blindTreatment

Summary

To assess the safety and efficacy of beyond time window TNK intravenous thrombolysis for distal Medium Vessel Occlusion (MeVO) related stroke in a prospective randomized clinical trial.

Timeline

Start
2024-10-02
Primary completion
2026-09-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous

Indications